

## Special Issue

# MRI and PET Imaging in Neuro-Oncology—Current Developments and Clinical Translation

### Message from the Guest Editors

Imaging biomarkers by means of magnetic resonance imaging (MRI) and positron emission tomography (PET) techniques are increasingly applied in the clinic, with a fast-growing body of evidence regarding their diagnostic value in neuro-oncology. In contrast to biochemical or histological markers, the key advantages of imaging biomarkers are the non-invasive nature and spatial and temporal resolution of these approaches. This Special Issue of *Cancers* focuses on new technical developments and clinical applications of novel MR biomarkers in humans, with a strong focus on neuro-oncologic diseases. These include both validation studies with clinically established biomarkers and novel approaches that have recently demonstrated high potential for clinical utility.

### Guest Editors

Prof. Dr. Daniel Paech

1. Division of Radiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
2. Clinic for Neuroradiology, University Hospital Bonn, Venusberg-Campus 1, Bonn University, 53127 Bonn, Germany

Dr. Manuel Röhrich

Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), D-68120 Heidelberg, Germany

### Deadline for manuscript submissions

closed (31 January 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/133705](https://mdpi.com/si/133705)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)